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ABSTRACT
Objective: This study investigated whether serum bilirubin levels can predict the progression 
of carotid atherosclerosis in individuals with type 2 diabetes mellitus (T2DM).
Methods: This observational study included 1,381 subjects with T2DM in whom serial 
measurements of carotid intima-media thickness (CIMT) were made at 1- to 2-year intervals 
for 6–8 years. The progression of carotid atherosclerosis was defined as newly detected 
plaque lesions on repeat ultrasonography. After dividing total serum bilirubin levels into 
tertiles, the association between total serum bilirubin at baseline and plaque progression 
status was analyzed.
Results: Among 1,381 T2DM patients, 599 (43.4%) were categorized as having plaque 
progression in their carotid arteries. Those with plaque progression were significantly older; 
showed a higher prevalence of hypertension, abdominal obesity, and chronic kidney disease; 
and had a longer duration of T2DM, higher levels of total cholesterol (TC), triglycerides, 
and insulin resistance, and lower total bilirubin concentrations than those with no plaque 
progression. When total serum bilirubin levels were divided into tertiles, the highest tertile 
group was younger than the lowest tertile group, with higher levels of TC and high-density 
lipoprotein cholesterol. Multiple logistic regression analysis demonstrated that higher 
serum bilirubin levels were associated with a significantly lower risk of CIMT progression 
(odds ratio, 0.584; 95% confidence interval, 0.392–0.870; p=0.008). Age (p<0.001), body 
mass index (p=0.023), and TC (p=0.019) were also associated with the progression of carotid 
atherosclerosis in T2DM patients.
Conclusion: Total serum bilirubin is independently associated with progression of 
atherosclerosis in the carotid arteries in T2DM patients.
Keywords: Diabetes mellitus, type 2; Bilirubin; Carotid intima-media thickness; 
Atherosclerosis
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INTRODUCTION
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with 
type 2 diabetes mellitus (T2DM).1 Diabetes roughly doubles the risk of CVD,2 with the main 
risk factors being components of metabolic syndrome, such as abdominal obesity, high 
blood pressure, and elevated plasma levels of triglycerides (TG).1 In recent years, many 
epidemiological studies have focused on identifying emerging cardiovascular risk factors, 
including non-alcoholic fatty liver disease (NAFLD) and genetic mutations such as clonal 
hematopoiesis.3,4 These approaches are important for the prevention of macrovascular 
complications among patients with T2DM and can be further utilized as predictive tools or 
therapeutic candidates.
Bilirubin, which is produced by heme oxygenase (HO)-1, a rate-limiting enzyme in heme 
degradation, is known to have anti-inflammatory and antioxidative effects.5 In 1994, the 
first clinical study reported that low bilirubin levels were associated with an increased risk 
of coronary artery disease.6 However, most association studies conducted on this topic used 
cross-sectional designs and few studies have been conducted in patients with T2DM.7-9
Therefore, the aim of this study was to investigate the associations between total serum 
bilirubin levels and carotid atherosclerosis progression in Korean T2DM patients.
MATERIALS AND METHODS
1. Study population
The Seoul Metabolic Syndrome Cohort, which recruited a total of 13,296 patients at Huh's 
Diabetes Center and the 21st Century Diabetes and Vascular Research Institute, has been 
previously described.3,10 In this study, we included 1,381 T2DM patients over 19 years of 
age, for whom data on repeated carotid artery ultrasonography over up to 8 years of follow-
up and total serum bilirubin levels were available. T2DM was defined using the American 
Diabetes Association classification.11 Patients under 19 years old; those with type 1 diabetes, 
pregnancy, liver diseases other than NAFLD (e.g., autoimmune or viral hepatitis), or a history 
of heavy alcohol consumption (210 g/week for men and 140 g/week for women); and those 
for whom it was difficult to judge the progression of bilateral carotid artery plaques by repeat 
ultrasonography were excluded from this study. The Institutional Review Board of Yonsei 
University approved this study (IRB NO. 4-2019-1183) and the requirement to obtain written 
informed consent was waived due to the retrospective study design.
2. Measurements of clinical and laboratory variables
At patients' initial visits, various clinical and laboratory parameters were collected. We 
used a self-report questionnaire to acquire social and medical histories, including smoking 
status, alcohol use, past and current history of medications, and the year of diabetes 
diagnosis. Well-trained nurses measured patients' height, weight, and waist circumference. 
For laboratory data, patients were required to fast at least 8 hours to ensure accurate 
measurements of fasting plasma glucose, total cholesterol (TC), TG, and high-density 
lipoprotein cholesterol (HDL-C). Other laboratory data such as glycated hemoglobin 
(HbA1c), blood urea nitrogen, creatinine, and total bilirubin were also obtained on the same 
day of collection.
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Chronic kidney disease (CKD) was defined as at least stage III (estimated glomerular 
filtration rate <60 mL/min/1.73 m2 for over 3 months), using the Modification of the Diet in 
Renal Disease equation.12
Patients' insulin sensitivity was assessed using the short insulin tolerance test, which 
measures the rate of plasma glucose disappearance (Kitt, %/min).13 The test was done at 
8:00 AM after an overnight fast. After an intravenous bolus injection of prediluted regular 
insulin (0.1 U/kg Humulin; Eli Lilly, Indianapolis, IN, USA), venous blood samples were 
collected at 3-minute intervals over the course of 0 to 15 minutes. To measure plasma 
glucose concentrations, a Beckman glucose analyzer II (Beckman Coulter Inc., Brea, CA, 
USA) was used, and the analysis was done immediately after sampling. Kitt was determined 
by calculating the slope of the decrease in log-transformed plasma glucose during 3 to 15 
minutes, and a Kitt below 2.5%/min was defined as indicating insulin resistance.14 To prevent 
potential hypoglycemia, a 100-mL solution of 20% dextrose was infused intravenously 
immediately after the test.
3.  Carotid ultrasonography and definition of the progression of atherosclerosis
Participants underwent carotid ultrasonography at least twice to evaluate their carotid 
atherosclerosis status throughout the study period. Each common carotid artery was scanned 
by high-resolution ultrasonography with a 10-MHz linear probe (LOGIQ7; GE, Milwaukee, 
WI, USA) by trained technicians who were blinded to patients' baseline data. Using a lateral 
longitudinal projection, the common carotid artery was scanned at the middle and distal 
parts. Measurements of carotid intima-media thickness (CIMT) were made at the far walls 
of the middle and distal common carotid artery, at a point 1 cm proximal from the carotid 
bulb. CIMT was defined as the distance (in millimeters) between 2 interfaces (lumen-intima 
and media-adventitia, respectively). The mean value from 3 measurements on each side was 
used. Carotid atherosclerosis progression was defined as the presence of a newly developed 
carotid plaque on repeated ultrasonography. A carotid plaque was defined by 1) the presence 
of a distinct hyperechogenic area, 2) CIMT greater than or equal to 1.5 mm, and/or 3) 
atherosclerotic protrusion into the arterial lumen with at least 50% greater thickness than the 
surrounding area, as previously described.15
4. Statistical analysis
Continuous variables were expressed as mean±standard deviation, and categorical variables 
were expressed as number (percentage). Baseline characteristics were compared between 
patients with and without plaque progression. We used the t-test for continuous variables and 
the χ2 test for categorical variables. Tertiles of total serum bilirubin levels were determined 
after stratification by sex. One-way analysis of variance was done for 3-group comparisons. 
Multivariable logistic regression analysis was performed to determine the factors predicting 
plaque progression with adjustment for confounding variables. SPSS version 25.0 (IBM 




Among 1,381 T2DM patients, 599 (43.4%) experienced carotid plaque progression during 
the follow-up period. The baseline characteristics of the subjects according to the status 
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of plaque progression in the carotid arteries are shown in Table 1. Patients with plaque 
progression had significantly distinct characteristics from those with no plaque progression; 
their mean age was older (59.6±9.2 vs. 54.0±9.9 years, p<0.001), hypertension was more 
prevalent (34.3% vs. 27.7%, p=0.009), waist circumference was higher (84.7±8.1 vs 82.7±8.5 
cm, p<0.001), T2DM duration was longer (6.9±6.6 vs. 5.8±5.7 years, p=0.001), insulin 
resistance index was poorer (2.1±1.0 vs. 2.2±1.0, p=0.006), TC levels (203.3±39.1 vs. 
192.8±42.7 mg/dL, p<0.001) and TG levels (157.3±90.7 vs. 142.1±116.8 mg/dL, p=0.009) were 
higher, the percentage of patients with CKD stage ≥3 was higher (9.0% vs. 6.2%, p=0.044), 
total serum bilirubin levels were lower (0.80±0.40 vs. 0.87±0.40 mg/dL, p<0.001), and the 
percentage of statin use was lower (9.0% vs. 12.9%, p=0.023). Statistically insignificant 
between-group differences were found for other characteristics, such as sex, body mass index 
(BMI), alcohol use, smoking, HbA1c, HDL-C levels, insulin use, sulfonylurea use, metformin 
use, thiazolidinedione use, and aspirin use.
2. Clinical characteristics according to tertiles of total serum bilirubin
As total serum bilirubin levels were significantly lower in patients with plaque progression, 
we investigated whether patients' baseline characteristics differed by bilirubin levels. 
When the data were analyzed according to serum bilirubin levels divided into tertiles, 
several variables showed statistically significant differences. Compared to the lowest 
tertile group, the highest tertile group was younger (56.7±10.0 vs. 55.1±9.3 years, p<0.001), 
contained a smaller proportion of patients using metformin (28.5% vs. 35.9%, p=0.015) and 
thiazolidinedione (5.4% vs. 12.5%, p<0.001), and had higher levels of TC (198.4±42.3 vs. 
192.5±39.1 mg/dL, p=0.012) and HDL-C (52.8±5.8 vs. 48.7±14.6 mg/dL, p<0.001) (Table 2). 
Statistically insignificant relationships were found for other variables, such as BMI, T2DM 
duration, and HbA1c levels.
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Table 1. Baseline characteristics
Characteristics No plaque progression (n=782) Plaque progression (n=599) p-value
Age (yr) 54.0±9.9 59.6±9.2 <0.001
Male sex 365 (46.7) 277 (46.2) 0.873
BMI (kg/m2) 24.4±3.1 24.8±3.1 0.065
Alcohol use 300 (41.9) 208 (38.4) 0.217
Smoking 277 (39.7) 209 (42.6) 0.330
HTN 217 (27.7) 205 (34.3) 0.009
Waist circumference (cm) 82.7±8.5 84.7±8.1 <0.001
DM duration (yr) 5.8±5.7 6.9±6.6 0.001
HbA1c (%) 8.4±2.0 8.5±1.8 0.183
Kitt (%/min) 2.2±1.0 2.0±1.0 0.006
TC (mg/dL) 192.8±42.7 203.3±39.1 <0.001
TG (mg/dL) 142.1±116.8 157.3±90.7 0.009
HDL-C (mg/dL) 51.2±14.2 50.5±17.1 0.397
eGFR <60 mL/min/1.73 m2 48 (6.2) 54 (9.0) 0.044
Total bilirubin (mg/dL) 0.87±0.40 0.80±0.40 <0.001
Insulin use 52 (6.6) 50 (8.4) 0.228
Sulfonylurea use 366 (46.8) 286 (47.8) 0.706
Metformin use 274 (35.5) 188 (31.4) 0.160
Thiazolidinedione use 63 (8.1) 55 (9.2) 0.453
Statin use 101 (12.9) 54 (9.0) 0.023
Aspirin use 89 (11.4) 72 (12.0) 0.714
Values are number (%) or mean±standard deviation.
BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; HbA1c, glycated hemoglobin; Kitt, rate 
constant for plasma glucose disappearance; TC, total cholesterol; TG, triglycerides; HDL-C, high-density 
lipoprotein cholesterol; eGFR, estimated glomerular filtration rate test.
3.  Association between total serum bilirubin and the progression of carotid 
atherosclerosis
Fig. 1 shows the percentage of plaque progression in each tertile of total serum bilirubin 
levels. In the lowest and middle tertiles, 45.8% and 46.8% of patients showed progression of 
carotid artery plaques, respectively. However, only 37.9% of patients in the highest tertile had 
plaque progression, which was a statistically significant difference (p for trend=0.014).
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Table 2. Clinical and laboratory parameters according to tertiles of serum bilirubin levels
Characteristics T1 T2 T3 (highest) p-value
Age (yr) 56.7±10.0 57.6±10.4 55.1±9.3 <0.001
Male sex 226 (54.5) 171 (35.6) 245 (50.5) 0.365
BMI (kg/m2) 24.5±3.1 24.7±3.2 24.6±3.1 0.688
Alcohol use 171 (45.0) 151 (35.1) 186 (41.6) 0.391
Smoking 171 (47.1) 131 (32.8) 184 (43.3) 0.370
HTN 125 (30.1) 157 (32.7) 140 (28.9) 0.643
Waist circumference (cm) 84.1±8.5 83.3±8.5 83.3±8.2 0.357
DM duration (yr) 6.6±6.4 6.3±6.0 6.0±6.0 0.388
HbA1c (%) 8.5±2.0 8.4±1.9 8.5±2.0 0.730
Kitt (%/min) 2.1 ± 1.0 2.2±0.9 2.1±1.0 0.380
TC (mg/dL) 192.5±39.1 200.6±42.3 198.4±42.3 0.012
TG (mg/dL) 147.8±110.4 153.2±98.1 144.8±111.4 0.477
HDL-C (mg/dL) 48.7±14.6 50.8±15.9 52.8±15.8 <0.001
eGFR <60 mL/min/1.73 m2 413 (8) 479 (8) 384 (6) 0.502
Total bilirubin (mg/dL) 0.5±0.1 0.7±0.1 1.2±0.4 <0.001
Insulin use 36 (8.7) 27 (5.6) 39 (8.0) 0.781
Sulfonylurea use 201 (48.4) 228 (47.5) 223 (46.0) 0.459
Metformin use 149 (35.9) 175 (36.5) 138 (28.5) 0.015
Thiazolidinedione use 52 (12.5) 40 (8.3) 26 (5.4) <0.001
Statin use 45 (10.8) 65 (13.5) 45 (9.3) 0.406
Values are number (%) or mean±standard deviation.
BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; HbA1c, glycated hemoglobin; TC, total 
cholesterol; TG, triglycerides; Kitt, rate constant for plasma glucose disappearance; HDL-C, high-density 
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p for trend=0.014
Fig. 1. Impact of serum bilirubin levels on the progression of carotid atherosclerosis. The percentage of patients 
experiencing plaque progression in each tertile of total bilirubin is shown. In the first tertile of serum bilirubin 
levels, the percentage of patients experiencing plaque progression was 45.8% (i.e., 54.2% did not show plaque 
progression). In the second tertile of serum bilirubin levels, 46.8% of patients showed plaque progression, and 
in the third tertile, the corresponding percentage was 37.9%. Using the linear by linear association method, the 
percentage of patients with plaque progression was found to show a decreasing trend with increasing serum 
bilirubin tertile (p=0.14).
As the progression of carotid atherosclerosis is a complex process that can be affected by 
many confounding clinical and laboratory parameters, multivariable logistic regression 
analyses were conducted (Table 3). In a fully-adjusted model, total serum bilirubin levels 
were associated with a significantly decreased risk of progression in CIMT by 42% (odds 
ratio [OR], 0.584; 95% confidence interval [CI], 0.392–0.870; p=0.008). Other variables 
that showed statistical significance for predicting the progression of carotid atherosclerosis 
were age (OR, 1.062; 95% CI, 1.044–1.080; p<0.001), BMI (OR, 1.056; 95% CI, 1.007–1.107; 
p=0.023), and TC (OR, 1.005; 95% CI, 1.001–1.008; p=0.019).
DISCUSSION
The present study of a longitudinal T2DM cohort with carotid ultrasonography data from 
an 8-year follow-up clearly demonstrated that patients with plaque progression showed 
significantly lower levels of total serum bilirubin than those with no plaque progression. 
Individuals with higher total serum bilirubin levels tended to be younger and to have higher TC 
and HDL-C levels than those with lower total serum bilirubin levels. After full adjustment for 
multiple confounding factors, total serum bilirubin levels were significantly associated with a 
42% decrement in the risk of plaque progression in the carotid arteries in T2DM patients.
Several studies have shown an inverse association between serum bilirubin levels and the 
risk of CVD. Schwertner et al.6 showed a significant negative correlation between bilirubin 
concentrations and the prevalence of coronary artery disease in a cross-sectional study of 
a non-diabetic population. Since then, many studies on this topic have been conducted, 
consistently demonstrating that lower bilirubin levels are associated with a higher risk of 
early familial coronary artery disease,16 ischemic stroke,17 coronary artery calcification,18 
and CIMT.8 Additionally, a meta-analysis confirmed the existence of an inverse relationship 
between serum bilirubin levels and the risk of incident CVD in the general population.19
However, most studies have included a limited proportion of T2DM patients. The association 
between serum bilirubin levels and CVD has not been sufficiently investigated among patients 
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Table 3. Associations of clinical and laboratory parameters with the progression of carotid atherosclerosis
Characteristics OR (95% CI) p-value
Age (yr) 1.062 (1.044–1.080) <0.001
Male sex 0.776 (0.490–1.229) 0.280
BMI (kg/m2) 1.056 (1.007–1.107) 0.023
Alcohol use 1.192 (0.847–1.676) 0.313
Smoking 1.234 (0.798–1.908) 0.344
HTN 1.170 (0.860–1.592) 0.318
DM duration, years 1.022 (1.000–1.045) 0.052
HbA1c (%) 1.075 (0.995–1.161) 0.065
Kitt (%/min) 1.023 (0.877–1.192) 0.773
TC (mg/dL) 1.005 (1.001–1.008) 0.019
TG (mg/dL) 1.001 (0.999–1.002) 0.289
HDL-C (mg/dL) 1.001 (0.992–1.010) 0.856
eGFR <60 mL/min/1.73m2 0.908 (0.530–1.556) 0.726
Total bilirubin (mg/dL) 0.584 (0.392–0.870) 0.008
Statin use 0.788 (0.511–1.215) 0.280
Aspirin use 1.265 (0.846–1.893) 0.252
OR, odds ratio; CI, confidence interval; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; 
HbA1c, glycated hemoglobin; Kitt, rate constant for plasma glucose disappearance; TC, total cholesterol; TG, 
triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate test.
with T2DM. A cross-sectional study reported that low bilirubin levels were significantly 
associated with arterial stiffness measured by the brachial-ankle pulse wave velocity in women 
with T2DM, but not in men.20 Another cross-sectional study of 6,713 patients with T2DM 
showed no significant association between low bilirubin levels and an increased risk of CVD.21 
However, the investigators explored the interaction of serum uric acid and bilirubin levels, and 
demonstrated that the concomitant presence of both high serum uric acid and low bilirubin 
levels was associated with a strongly increased risk for CVD in T2DM patients.
Our cohort data further demonstrated that conventional cardiovascular risk factors such as 
age, obesity, and TC were significantly associated with the deterioration of carotid plaques 
in T2DM patients. In a study of the general population, age, smoking, high blood pressure, 
low-density lipoprotein cholesterol, and HDL-C were found to be significantly related to 
progression of the mean CIMT.22 A Norwegian study of 13-year follow-up cohort data with 
more than 2,700 participants found that age, male sex, TC, systolic blood pressure, and 
smoking were significant predictors of the total plaque area measured by ultrasonography, 
whereas BMI and diabetes did not show a significant relationship.23 A previous study of T2DM 
patients with a mean follow-up period of 31 months reported that the presence of peripheral 
arterial disease and low HDL-C levels were predictors of the occurrence of carotid plaques, 
while diastolic blood pressure and BMI were associated with the maximal CIMT and mean 
CIMT, respectively.24 A Japanese study of T2DM patients showed that age and average HbA1c 
during a 3.1-year follow-up predicted the progression of CIMT.25 Similar to their findings, 
our data also revealed a marginal association between baseline HbA1c and carotid plaque 
progression (OR, 1.075; p=0.065).
Extensive in vitro and in vivo research has explored the mechanisms of the protective effects 
of bilirubin. Atherosclerosis is a very complex disease process, and bilirubin is known to be 
able to influence various stages of atherosclerosis, from initiation to progression, through 
multiple mechanisms, including its antioxidant and anti-inflammatory effects, inhibition 
of smooth muscle cell proliferation, improvement of endothelial function, and alteration of 
lipoproteins. First, bilirubin has been shown to exert powerful antioxidant activity against 
lipoprotein oxidation in vascular smooth-muscle cells.26 An in vivo study using an animal 
model of hyperbilirubinemia (Gunn rats) showed that bilirubin exerted a protective effect 
against oxidative damage in the plasma of rats with jaundice when exposed to hyperoxia.27 
Consistent with animal studies, exogenously applied bilirubin was found to inhibit the 
effects of HO-1 and to suppress chemotactic activity in monocytes.28 Additionally, bilirubin 
attenuated the overexpression of adhesion molecules via inhibition of the nuclear factor-κB 
pathway and inhibited the endothelial adhesion of polymorphonuclear leukocytes induced 
by tumor necrosis factor alpha.29,30 In addition to influencing the inflammatory process of 
atherosclerosis, bilirubin could prevent neointimal formation by inhibiting the proliferation 
of vascular smooth muscle cells (VSMCs). In hyperbilirubinemic Gunn rats and wild-type rats 
treated with biliverdin, bilirubin attenuated balloon injury-induced neointimal formation 
and inhibited progression through the cell cycle in smooth muscle cells via inhibition of the 
mitogen-activated protein kinase signaling pathways.31 Administration of exogenous bilirubin 
has also been found to inhibit neointimal formation after an arterial injury.32 Several studies 
have shown that bilirubin changed the composition of lipoproteins, especially apolipoprotein 
A1 and B.33,34 Lastly, HO-1, which catalyzes the initial, rate-limiting step of heme catabolism 
and bilirubin formation, is well known to exert various protective effects against vascular 
complications of diabetes. In experimental models of atherosclerotic CVD, HO-1−/−apoE−/− 
mice showed more advanced atherosclerotic lesion formation than HO-1+/+apoE−/− mice,35 and 
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VSMCs isolated from HO-1 knockout mice were much more susceptible to oxidative stress, 
leading to cell death, than those isolated from control mice.36
The current study has some limitations. Due to the lack of outcome data regarding 
cardiovascular events and mortality, we were unable to assess the association between total 
serum bilirubin levels and clearly-defined outcome parameters. However, CIMT is a reliable 
surrogate index for predicting the future development of cardiovascular and cerebrovascular 
diseases. Furthermore, a retrospective study design has intrinsic drawbacks in determining 
whether low total serum bilirubin levels are merely a predictor of the progression of 
atherosclerosis in T2DM patients, or whether they may play a causal role in this process. 
Dynamic changes in medication during the follow-up period were not fully adjusted in this 
study. Nevertheless, a strength of the present study is that it is the first study to investigate the 
longitudinal relationship between carotid plaque progression and serum bilirubin levels in a 
large number of T2DM participants who periodically underwent a detailed examination with 
a relatively long follow-up.
In conclusion, this longitudinal analysis demonstrated that higher levels of total serum 
bilirubin were significantly associated with a lower incidence of plaque progression in the 
carotid arteries in T2DM patients. A prospective study design or mendelian randomization 
approach would be needed to conclusively determine the impact of total serum bilirubin 
levels on the progression of atherosclerosis in T2DM. These will allow us to understand 
whether bilirubin plays a predictive or causative role for cardiovascular and cerebrovascular 
complications in T2DM patients.
REFERENCES
 1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its 
complications. Nat Rev Endocrinol 2018;14:88-98. 
PUBMED | CROSSREF
 2. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes 
mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis 
of 102 prospective studies. Lancet 2010;375:2215-2222. 
PUBMED | CROSSREF
 3. Kim SK, Choi YJ, Huh BW, Park SW, Lee EJ, Cho YW, et al. Nonalcoholic Fatty liver disease is associated 
with increased carotid intima-media thickness only in type 2 diabetic subjects with insulin resistance. J 
Clin Endocrinol Metab 2014;99:1879-1884. 
PUBMED | CROSSREF
 4. Han E, Lee YH. Non-alcoholic fatty liver disease: the emerging burden in cardiometabolic and renal 
diseases. Diabetes Metab J 2017;41:430-437. 
PUBMED | CROSSREF
 5. Lee EY, Lee YH, Kim SH, Jung KS, Kwon O, Kim BS, et al. Association between heme oxygenase-1 
promoter polymorphisms and the development of albuminuria in type 2 diabetes: a case-control study. 
Medicine (Baltimore) 2015;94:e1825. 
PUBMED | CROSSREF
 6. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased 
risk of coronary artery disease. Clin Chem 1994;40:18-23.
PUBMED
 7. Hamur H, Duman H, Demirtas L, Bakirci EM, Durakoglugil ME, Degirmenci H, et al. Total bilirubin levels 
predict subclinical atherosclerosis in patients with prediabetes. Angiology 2016;67:909-915. 
PUBMED | CROSSREF
 8. Dullaart RP, Kappelle PJ, de Vries R. Lower carotid intima media thickness is predicted by higher serum 
bilirubin in both non-diabetic and Type 2 diabetic subjects. Clin Chim Acta 2012;414:161-165. 
PUBMED | CROSSREF
202https://doi.org/10.12997/jla.2020.9.1.195





 9. Kawamoto R, Ninomiya D, Hasegawa Y, Kasai Y, Kusunoki T, Ohtsuka N, et al. Mildly elevated serum 
total bilirubin levels are negatively associated with carotid atherosclerosis among elderly persons with 
type 2 diabetes. Clin Exp Hypertens 2016;38:107-112. 
PUBMED | CROSSREF
 10. Choe EY, Lee YH, Choi YJ, Huh BW, Lee BW, Kim SK, et al. Waist-to-calf circumstance ratio is an 
independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. J Gastroenterol 
Hepatol 2018;33:1082-1091. 
PUBMED | CROSSREF
 11. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in 
Diabetes-2019. Diabetes Care 2019;42:S13-S28. 
PUBMED | CROSSREF
 12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 
1999;130:461-470. 
PUBMED | CROSSREF
 13. Sharma R, Vikram NK, Misra A. Comparison of short insulin tolerance test with HOMA Method for 
assessment of insulin sensitivity in Asian Indians in north India. Diabetes Res Clin Pract 2008;82:e9-e12. 
PUBMED | CROSSREF
 14. Lee MY, Koh JH, Nam SM, Jung PM, Sung JK, Kim SY, et al. Short insulin tolerance test can determine the 
effects of thiazolidinediones treatment in type 2 diabetes. Yonsei Med J 2008;49:901-908. 
PUBMED | CROSSREF
 15. Qi Y, Fan J, Liu J, Wang W, Wang M, Sun J, et al. Cholesterol-overloaded HDL particles are independently 
associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a 
community-based cohort study. J Am Coll Cardiol 2015;65:355-363. 
PUBMED | CROSSREF
 16. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is 
associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 
1996;16:250-255. 
PUBMED | CROSSREF
 17. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a 
prospective study in Korean men and women. Stroke 2009;40:3422-3427. 
PUBMED | CROSSREF
 18. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-
extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 
to 2004. Arterioscler Thromb Vasc Biol 2008;28:166-172. 
PUBMED | CROSSREF
 19. Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of 
incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol 2015;35:716-724. 
PUBMED | CROSSREF
 20. Kim ES, Mo EY, Moon SD, Han JH. Inverse association between serum bilirubin levels and arterial 
stiffness in Korean women with type 2 diabetes. PLoS One 2014;9:e109251. 
PUBMED | CROSSREF
 21. Ren Y, Jin N, Hong T, Mu Y, Guo L, Ji Q, et al. Interactive effect of serum uric acid and total bilirubin for 
cardiovascular disease in Chinese patients with type 2 diabetes. Sci Rep 2016;6:36437. 
PUBMED | CROSSREF
 22. Rosvall M, Persson M, Östling G, Nilsson PM, Melander O, Hedblad B, et al. Risk factors for the 
progression of carotid intima-media thickness over a 16-year follow-up period: the Malmö Diet and 
Cancer Study. Atherosclerosis 2015;239:615-621. 
PUBMED | CROSSREF
 23. Herder M, Johnsen SH, Arntzen KA, Mathiesen EB. Risk factors for progression of carotid intima-media 
thickness and total plaque area: a 13-year follow-up study: the Tromsø Study. Stroke 2012;43:1818-1823. 
PUBMED | CROSSREF
 24. Bosevski M, Stojanovska L. Progression of carotid-artery disease in type 2 diabetic patients: a cohort 
prospective study. Vasc Health Risk Manag 2015;11:549-553. 
PUBMED | CROSSREF
 25. Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuhisa M, Kajimoto Y, et al. Carotid intima-media 
thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident 
coronary heart disease. Diabetes Care 2000;23:1310-1315. 
PUBMED | CROSSREF
203https://doi.org/10.12997/jla.2020.9.1.195





 26. Clark JE, Foresti R, Green CJ, Motterlini R. Dynamics of haem oxygenase-1 expression and bilirubin 
production in cellular protection against oxidative stress. Biochem J 2000;348:615-619. 
PUBMED | CROSSREF
 27. Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. Hyperbilirubinemia results in reduced 
oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 1995;19:395-404. 
PUBMED | CROSSREF
 28. Morita T, Imai T, Yamaguchi T, Sugiyama T, Katayama S, Yoshino G. Induction of heme oxygenase-1 in 
monocytes suppresses angiotensin II-elicited chemotactic activity through inhibition of CCR2: role of 
bilirubin and carbon monoxide generated by the enzyme. Antioxid Redox Signal 2003;5:439-447. 
PUBMED | CROSSREF
 29. Mazzone GL, Rigato I, Ostrow JD, Bossi F, Bortoluzzi A, Sukowati CH, et al. Bilirubin inhibits the 
TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 
2009;386:338-344. 
PUBMED | CROSSREF
 30. Mazzone GL, Rigato I, Ostrow JD, Tiribelli C. Bilirubin effect on endothelial adhesion molecules 
expression is mediated by the NF-kappaB signaling pathway. Biosci Trends 2009;3:151-157.
PUBMED
 31. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, et al. Bilirubin: a natural inhibitor of vascular 
smooth muscle cell proliferation. Circulation 2005;112:1030-1039. 
PUBMED | CROSSREF
 32. Peyton KJ, Shebib AR, Azam MA, Liu XM, Tulis DA, Durante W. Bilirubin inhibits neointima formation 
and vascular smooth muscle cell proliferation and migration. Front Pharmacol 2012;3:48. 
PUBMED | CROSSREF
 33. O'Kane MJ, Lynch PL, Callender ME, Trimble ER. Abnormalities of serum apo A1 containing lipoprotein 
particles in patients with primary biliary cirrhosis. Atherosclerosis 1997;131:203-210. 
PUBMED | CROSSREF
 34. Levinson SS. Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Ann Clin 
Lab Sci 1997;27:185-192.
PUBMED
 35. Yet SF, Layne MD, Liu X, Chen YH, Ith B, Sibinga NE, et al. Absence of heme oxygenase-1 exacerbates 
atherosclerotic lesion formation and vascular remodeling. FASEB J 2003;17:1759-1761. 
PUBMED | CROSSREF
 36. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, et al. Heme oxygenase-1 protects against vascular 
constriction and proliferation. Nat Med 2001;7:693-698. 
PUBMED | CROSSREF
204https://doi.org/10.12997/jla.2020.9.1.195
Bilirubin and Carotid Atherosclerosis
https://e-jla.org
Journal of 
Lipid and 
Atherosclerosis
